Recent advances in bone marrow failure

[SY9-1] Nontransplant therapy for aplastic anemia

Danielle Townsley (Oncology, Clinical Development, MedImmune, United States of America)

Dr. Danielle Townsley is an Associate Director in Clinical Development, Oncology at Medimmune in Gaithersburg, Maryland. She received a Bachelor’s Degree at the University of California, San Diego in 1999 and a Master’s Degree in Epidemiology from the University of Edinburgh, Scotland in 2002. She completed her MD in 2006 and internal medicine residency at the George Washington University in 2009. In 2011, she completed her hematology fellowship at the NIH and subsequently became a principal investigator on multiple clinical trials within the bone marrow failure program at the National Heart Lung and Blood Institute (NHLBI) under the leadership of Dr. Neal Young. She led clinical studies investigating the use of eltrombopag (Promacta) for aplastic anemia and myelodysplastic syndromes, and danazol for inherited bone marrow failure. Currently she oversees early stage development of biologic therapeutics for a variety of hematologic malignancies and solid tumors.